imatinib mesylate has been researched along with Incontinentia Pigmenti Achromians in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Chaturvedi, A; Thapa, M | 1 |
| do Carmo, LL; Mendonça, LG; Yung, AA | 1 |
| Robert, C; Sibaud, V | 1 |
| Akin Belli, A; Ayer, M; Barut, SG; Dervis, E | 1 |
| Blaeser, BF; Boyle, N; Dehni, WJ; Kabani, SP; Li, CC; Malik, SM; Toner, M; Woo, SB | 1 |
| Andersen, MK; Gerdes, AM; Hansen, TV; Wadt, K | 1 |
| Arora, B; Kochupillai, V; Kumar, L; Sharma, A; Wadhwa, J | 1 |
| Leach, M; McPartlin, S | 1 |
| Mcpherson, T; Sherman, V; Turner, R | 1 |
1 review(s) available for imatinib mesylate and Incontinentia Pigmenti Achromians
| Article | Year |
|---|---|
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles | 2013 |
1 trial(s) available for imatinib mesylate and Incontinentia Pigmenti Achromians
| Article | Year |
|---|---|
Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Exanthema; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pigmentation Disorders; Piperazines; Pyrimidines | 2004 |
7 other study(ies) available for imatinib mesylate and Incontinentia Pigmenti Achromians
| Article | Year |
|---|---|
Imatinib-induced melanonychia in a patient of chronic myeloid leukaemia: rarely reported side effect.
Topics: Adult; Antineoplastic Agents; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nail Diseases; Pigmentation Disorders | 2020 |
Imatinib-Related Conjunctival Pigmentation.
Topics: Aged; Antineoplastic Agents; Conjunctival Diseases; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Pigmentation Disorders | 2018 |
Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A six-year follow up.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Cheilitis; Cross-Sectional Studies; Drug Eruptions; Edema; Exanthema; Female; Follow-Up Studies; Humans; Hyperhidrosis; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pigmentation Disorders; Stomatitis, Aphthous; Time Factors; Young Adult | 2016 |
Mucosal pigmentation caused by imatinib: report of three cases.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mouth Mucosa; Palate, Hard; Pigmentation Disorders; Piperazines; Pyrimidines | 2012 |
[A new genetic diagnosis of familiar gastrointestinal stromal tumour].
Topics: Aged; Antineoplastic Agents; Benzamides; Family; Fatal Outcome; Female; Gastrointestinal Stromal Tumors; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Imatinib Mesylate; Intestinal Neoplasms; Male; Middle Aged; Mutation, Missense; Pigmentation Disorders; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2012 |
Loss of skin pigment caused by imatinib therapy.
Topics: Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Pigmentation Disorders; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Pigmentation | 2005 |
Imatinib-associated hyperpigmentation, a side effect that should be recognized.
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pigmentation Disorders; Piperazines; Pyrimidines | 2009 |